Context: Dipeptidyl peptidase IV (DPP4) is overexpressed in thyroid cancer and certain malignancies. Furthermore, DPP4 has been identified as a discriminatory marker for thyroid cancer. However, it remains unclear whether DPP4 expression plays a prognostic role.
an attractive target in many fields such as tumor biology and immunology.
Thyroid cancer is the most common endocrine malignancy, and its incidence has substantially increased in recent decades (4) . Papillary thyroid cancer accounts for most thyroid cancers. The BRAF V600E mutation, which results in greater mitogen-activated protein kinase signaling output, is the most predominant oncogenic driver (5) . Evidence indicates that DPP4 expression is upregulated in malignant thyroid tumors, and DPP4 can be used as a malignancy marker in fine-needle aspiration cytology of thyroid nodules (6, 7) . Recently, DPP4 was included in a three-gene signature for preoperative diagnosis of thyroid cancer (8) . However, the functional significance of DPP4 expression in thyroid cancer remains uncertain.
Alterations in DPP4 expression and activity have been implicated in several solid and hematological malignancies (1) . DPP4 in malignant tumors may exert tumor-promoting or tumor-suppressing effects, depending on the cancer type and cellular context (9) . In the current study, we aimed to investigate the association between DPP4 expression and tumor aggressiveness of thyroid cancer. We also performed in vitro functional studies to determine the role of DPP4 in colony growth and cellular invasion. Furthermore, the therapeutic potential of DPP4 inhibition was evaluated in a xenograft tumor model.
Materials and Methods

Patients and tissues
The study (13MMHIS101) was approved by the Institutional Review Board of MacKay Memorial Hospital, Taipei, Taiwan. Tissue microarrays of thyroid cancer were constructed from paraffin-embedded specimens randomly selected from the pathological archives as previously described (10) . To be included in the study, patients were required to have undergone total thyroidectomy with or without lymph node dissection for thyroid cancer, with a tumor size of $8 mm. The choice of administering radioactive iodine was left to the discretion of the treating physician. The normal thyroid tissue of the contralateral lobe was collected and evaluated in parallel. BRAF V600E mutation testing was performed by Sanger sequencing and immunohistochemical staining (10) . Prognosis was evaluated via the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging (seventh edition); age, metastasis, extent, and size; metastases, age, completeness of resection, invasion, and size; and the American Thyroid Association modified initial risk stratification system (11) , which considers low-volume lymph nodal metastases as low risk.
Patients were usually followed every 3 months in the first year and at 3-to 6-month intervals thereafter, based on the risk of the individual patient and clinical need. During follow-up, serial physical examinations accompanied by neck ultrasound and chest X-ray were performed to detect possible persistent, recurrent, or metastatic lesions. Thyroglobulin (Tg) and thyroglobulin antibody (TgAb) levels were measured every 3 to 6 months. Most patients had undergone diagnostic iodine-131 scans 9 to 24 months after initial treatment, with concurrent measurement of stimulated serum Tg and TgAb levels. The clinical status at the time of last follow-up was defined as no evidence of disease (suppressed Tg ,1 ng/mL and no structurally detectable disease), indeterminate response (persistently measurable TgAb in the absence of structural disease), biochemical persistent disease (suppressed Tg $1 ng/mL without structural disease), structural persistent disease (locoregional or distant metastases with any Tg levels), and recurrence (structural or biochemical evidence of disease identified after a period of no evidence of disease).
Immunohistochemistry
Samples were subjected to standard deparaffinization, rehydration, and antigen retrieval for immunohistochemical staining as described previously (12) . The slides were incubated with primary antibody against DPP4 (ab114033; Abcam, Cambridge, UK) or transforming growth factor-b receptor I (TGFBR1) (sc-9048; Santa Cruz Biotechnology, Dallas, TX). Slides were examined separately by two independent investigators (T.-Y.W. and S.-P.C.) who were unaware of clinical data, and the results were pooled. DPP4 expression was quantitated via H-scores ranging from 0 to 300, defined by multiplying the percentage (0% to 100%) and intensity of staining (1 to 3+). We dichotomized the H-scores into low and high expression levels by a cutoff point determined in the X-tile software program (13) . DPP4 expression was considered to be high if an H-score was $200.
The Cancer Genome Atlas data set analysis
Gene expression data of The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) were downloaded as previously described (14) . We used log-transformed RNA-Seq by Expectation Maximization values as messenger RNA (mRNA) expression levels.
Cell culture and reagents
Human papillary thyroid cancer cell lines K1 and BCPAP were purchased from the European Collection of Cell Cultures (Salisbury, UK) and the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany), respectively. In our laboratory, cell lines have been periodically authenticated by short tandem repeat analysis and tested for being mycoplasma free. Sitagliptin and vildagliptin were purchased from Santa Cruz Biotechnology. PLX4032 (vemurafenib) was obtained from Selleck Chemicals (Houston, TX), and PD98059 was obtained from Sigma-Aldrich (St. Louis, MO). Recombinant human transforming growth factor (TGF)-b1 was purchased from R&D Systems (Minneapolis, MN).
Transfection
For knockdown studies, small interfering RNAs (siRNAs) targeting DPP4, TGFBR1, or nontargeting sequences were purchased from Santa Cruz Biotechnology. 
DPP4 activity
DPP4 enzyme activity was measured spectrophotometrically, with Gly-Prop-nitroanilide (Sigma) used as the chromogenic substrate for DPP4 (15) . Briefly, 5 3 10 5 cells were washed with phosphate-buffered saline and suspended in 200 mL of phosphate-buffered saline into 96-well plate, and the substrate was added at a final concentration of 0.24 mM. The absorption was measured at 405 nm before the addition of the substrate and after 60-minute incubation at 37°C.
Clonogenic, migration, and invasion assays
Colony formation assay was performed as previously described (12) . In brief, K1 (500 cells per well) or BCPAP (1500 cells per well) cells were seeded into six-well plates. After 13 days, colonies were stained with 3% crystal violet and examined by microscopy. Colonies containing .50 cells were counted in five nonoverlapping fields.
Cellular migration and invasion assays were performed in a Boyden chamber system with a pore size of 8 mm (Corning Life Sciences, Corning, NY). For invasion assays, inserts coated with Matrigel matrix were used. A total of 1 3 10 4 cells were seeded onto inserts in medium containing 1% fetal bovine serum, and the inserts were placed into a 24-well plate filled with medium containing 10% fetal bovine serum. The plates were incubated for 24 hours (K1 cells) or 48 hours (BCPAP cells) at 37°C. Cells on the lower surface of the membrane were fixed, stained with Diff-Quik (Sysmex, Kobe, Japan), imaged, and quantified with the ImageJ software.
Oligonucleotide microarray analysis
Two days after transfection with DPP4 or control scrambled siRNA, cells were harvested and mRNA expression profiling was performed via Agilent SurePrint G3 Human Gene Expression v2 8x60K Microarray. A twofold threshold was applied. Differentially expressed genes in both cell lines were subjected to Kyoto Encyclopedia of Genes and Genomes pathway analysis.
Western blot analysis
Protein samples were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting with the following antibodies: anti-DPP4 (ab129060; Abcam), anti-TGFBR1 (#3712; Cell Signaling Technology, Danvers, MA), anti-phospho-SMAD2 (ab188334; Abcam), anti-SMAD2/3 (#8685; Cell Signaling), anti-phospho-AKT (#4056; Cell Signaling), anti-AKT (#2920; Cell Signaling), anti-phospho-GSK3b (#5558; Cell Signaling), anti-GSK3b (#9315; Cell Signaling), and anti-b-actin (Sigma). The results were visualized with an enhanced chemiluminescence detection system (Amersham, GE Healthcare, Waukesha, WI).
Xenograft tumor assay
All animal care and experiments were approved by the Institutional Animal Care and Use Committee of MacKay Memorial Hospital. Six-week-old female BALB/c nude mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan. K1 cells (1 3 10 7 ) were injected subcutaneously into the bilateral flank of mice. Upon tumor establishment, mice were allocated to the treatment group (sitagliptin 20 mg/kg body weight, by mouth once daily 5 days per week) or the control group (saline). The tumor volume was calculated as length 3 width 2 3 0.5. Body weight and serum glucose levels were measured every week. At the mice were euthanized, tumors were resected, fixed in formalin, and paraffin embedded for hematoxylin and eosin and immunohistochemical staining.
Statistical analysis
Patient data were analyzed via Fisher's exact test, the x 2 test, the Cochran-Armitage trend test, or the Mann-Whitney U test, as appropriate. Associations between clinicopathological parameters and clinical status at final follow-up were first explored via univariate logistic regression analysis. Stepwise multiple logistic regression analysis was used to assess the independent effect of these variables on the presence of structural persistent disease or recurrent disease. Statistical analysis of the in vitro experiments was carried out via two-tailed Student t test or oneway analysis of variance. Analysis of variance was performed comparing the concentration-dependent effects of drug treatment with those of vehicle-treated controls, and the HolmSidak method was used to examine post hoc differences when indicated. A P value ,0.05 was considered statistically significant.
Results
DPP4 is overexpressed in malignant thyroid neoplasms
To determine the expression pattern of DPP4 in human thyroid tissues and neoplasms, immunohistochemical analysis was performed on 144 pairs of surgical samples from patients with thyroid cancer (Table 1 and  Supplemental Table 2 ). DPP4 staining was either cytoplasmic or both cytoplasmic and membranous, with enhancement at the plasma membrane [ Fig. 1(A-F) ]. The H-scores of papillary (169 6 88, n = 121), follicular (166 6 99, n = 14), poorly differentiated (176 6 103, n = 7), and anaplastic thyroid cancer (155 6 163, n = 2) were significantly higher than those of their corresponding normal tissues (24 6 19, n = 143, one missing). When the H-score $200 was chosen as a cutoff point, high DPP4 expression was observed in 60%, 64%, 71%, and 50% of papillary, follicular, poorly differentiated, and anaplastic cancer, respectively. There was no DPP4 expression in normal thyroid tissues or benign thyroid neoplasms. The results of immunohistochemical staining were confirmed by Western blot analysis. Representative Western blots of independent samples are shown in Supplemental Fig. 1(A) .
To investigate the significance of DPP4 overexpression in thyroid cancer, the association between DPP4 expression and clinicopathological features was analyzed in 121 patients with papillary thyroid cancer. As shown in Fig. 1(G) , the H-scores significantly increased with advanced TNM stage (P = 0.0007). High DPP4 expression was associated with a classic histology, extrathyroidal extension, and BRAF V600E mutation (Table 1) . There was a trend toward a higher risk of lymph node metastasis in tumors with high DPP4 expression (P = 0.054). In addition, several prognostic classification systems, including TNM stage (P = 0.007), AMES (P = 0.002), MACIS (P = 0.010), and the American Thyroid Association modified initial risk stratification (P , 0.001), suggested that papillary cancer with high DPP4 expression was associated with a poor patient outcome.
After a mean follow-up of 58 months, 71% (n = 86) of the patients were classified as having no evidence of disease, 5% (n = 6) as having indeterminate response, 9% (n = 11) as having biochemical persistent disease, 11% (n = 13) as having structural persistent disease, and 4% (n = 5) as having recurrent disease. Patients in the high-DPP4 expression group were less likely to be classified as having no evidence of disease at the time of final follow-up (P = 0.042). Additionally, H-scores of DPP4 tumor staining were significantly associated with clinical status at final follow-up [P = 0.018, Fig. 1(H)] . A post hoc analysis revealed that H-scores in the group with structural persistent disease were higher than H-scores in the group with no evidence of disease (P = 0.010). Although high DPP4 expression was associated with a higher likelihood of structural persistent disease or recurrent disease (Cochran-Armitage trend test P = 0.036), in multivariate logistic regression analysis, DPP4 expression was not an independent predictor of structural persistent disease or recurrent disease (Supplemental Table 3 ). To further corroborate these findings, an analysis of TCGA-THCA data showed that DPP4 expression was positively associated with extrathyroidal extension, BRAF mutation, and pathologic TNM stage (Supplemental Fig. 2 ). These results are in agreement with our findings, indicating that DPP4 expression is upregulated in thyroid carcinoma and may serve as a negative prognostic marker in papillary thyroid cancer.
DPP4 silencing decreases colony foci, cellular migration, and invasion
To evaluate whether cell line models recapitulate DPP4 expression patterns observed in patient tissues, we screened a panel of thyroid cancer cell lines for DPP4 expression. All screened thyroid cancer cell lines exhibited protein expression of DPP4 [Supplemental Fig. 1(B) ]. Given that DPP4 expression was associated with BRAF V600E mutation in our patients with papillary thyroid cancer, we further evaluated the effect of inhibiting mitogen-activated protein kinase pathway on DPP4 expression. Two human papillary thyroid cancer cell lines, K1 and BCPAP, were treated with BRAF and MEK inhibitors. As shown in Supplemental Fig. 1(C) , there was a reduction in DPP4 protein expression in the treated cells, suggesting that DPP4 may be a downstream target of mitogen-activated protein kinase pathway.
To test for a functional role of DPP4, papillary thyroid cancer cells were transfected with siRNA against DPP4. Successful knockdown of DPP4 expression was confirmed by real-time quantitative PCR and Western blotting, with .50% decrease in DPP4 mRNA and protein expression in the two cell lines tested. There was good knockdown of DPP4 protein expression for $10 days (data not shown). As expected, DPP4 silencing decreased DPP4 enzyme activity in both cell lines [ Fig. 2(A) ].
The effect of DPP4 silencing on the growth potential of tumor cells was assessed with a standard clonogenic assay. DPP4 knockdown resulted iñ 60% growth inhibition in the K1 cells and 70% inhibition of BCPAP cells [ Fig. 2(B) ]. Furthermore, cell migration and invasion were significantly decreased by~70% to 75% in papillary thyroid cancer cells with DPP4 knockdown [ Fig. 2(C) and 2(D) ]. These data suggest that DPP4 expression is critical for some oncogenic properties of thyroid cancer cells.
DPP4 enzymatic activity mediates malignant properties of thyroid cancer cells
We next evaluated the role of DPP4 enzymatic activity and expression in regulating malignant properties of thyroid cancer cells. Two DPP4 inhibitors (sitagliptin and vildagliptin) were tested. Both inhibitors reduced DPP4 enzyme activity in a dose-dependent manner [ Fig. 3(A) ]. DPP4 activity was virtually abolished in both cell lines after treatment with 1000 nM sitagliptin. Treatment with 1000 nM sitagliptin or vildagliptin for 24 to 72 hours did not affect the DPP4 expression (data not shown).
Treatment with 1000 nM sitagliptin or vildagliptin inhibited colony formation by 80% to 85% in K1 cells but had modest effects in BCPAP cells [~35% reduction; Fig. 3(B) ]. Moreover, treatment with 1000 nM sitagliptin effectively decreased cell migration and invasion (~70% to 80% reduction) in comparison with 1000 nM vildagliptin [50% to 70% reduction; Fig. 3(C) and 3(D) ]. To define the specificity of these DPP4 inhibitors, we also assessed the effects of DPP4 inhibitors in a breast cancer cell line (MDA-MB-231), which had no demonstrable DPP4 expression. As shown in Supplemental Fig. 3 , sitagliptin and vildagliptin did not significantly affect cell migration and invasion in the breast cancer cells. Taken together, pharmacological inhibition of DPP4 enzyme activity showed similar suppressive capacities to the genetic inhibition of DPP4 on colony formation, cell migration, and invasion in DPP4-expressing thyroid cancer cells.
TGF-b signaling pathway is involved in the regulatory effects of DPP4
Because little is known about the downstream targets of DPP4 in thyroid cancer cells, we carried out microarray analysis by using RNA samples from thyroid cancer cells transfected with a control scrambled siRNA or DPP4 siRNA to find out the potential effectors. Differentially expressed genes were defined as those exhibiting twofold or greater change in expression upon DPP4 silencing. In total, we identified 321 differentially expressed genes in K1 cells and 383 genes in BCPAP cells. The 82 overlapping genes are listed in Supplemental Table 4 . Kyoto Encyclopedia of Genes and Genomes pathway analysis of these differentially expressed genes demonstrated that TGF-b signaling pathway ranked at the top in significance [ Fig. 4(A) ]. Of note, TGFBR1 was closest to DPP4 in the hierarchical clustering tree. TGFBR1 (also known as ALK5) encodes the TGF-b type I receptor, which is activated by the TGF-b type II receptor after ligand binding. The activated receptors in turn phosphorylate SMAD2 and SMAD3 proteins, regulating interaction with SMAD4 and nuclear translocation to act as transcription factors (16) . There are also SMAD-independent noncanonical pathways directly activated by TGF-b receptors. To validate that TGF-b signaling pathway is a potential downstream effector of DPP4, we performed Western blots to investigate the expression of relevant proteins. As shown in Fig. 4(B) , DPP4 silencing in thyroid cancer cells was accompanied by attenuation of the expression of TGFBR1 and its downstream phosphorylated SMAD2. Furthermore, we observed a decreased phosphorylation of protein kinase B and its downstream GSK3b in association with interfering RNA knockdown of DPP4.
To test whether TGFBR1 is essential for the effects of DPP4 suppression, thyroid cancer cells were transfected with siRNA against TGFBR1. Cells with TGFBR1 knockdown had lower invasive capacity than those transfected with a control scrambled siRNA [ Fig. 4(C) ]. Moreover, sitagliptin lost its inhibitory effect on cell invasion after TGFBR1 knockdown. We also conducted a rescue experiment in which thyroid cancer cells with DPP4 silencing were stimulated with TGF-b1. The inhibitory effect on cell invasion caused by DPP4 knockdown was restored by TGF-b1 stimulation. Consistently, sitagliptininduced inhibition of cell invasion was attenuated by TGFb1 stimulation (Supplemental Fig. 4) .
Additional independent thyroid cancer samples (papillary n = 22, follicular n = 3, anaplastic n = 2) were subjected to immunohistochemical characterization of both DPP4 and TGFBR1 expressions. Interestingly, tumor cells showed cytoplasmic TGFBR1 immunoreactivity patterns that resembled those seen in immunostains for DPP4, though to a less extent (Supplemental Fig. 5 ). In accordance, as shown in Supplemental Fig. 6 , the TCGA-THCA data set showed that TGFBR1 expression was positively correlated with DPP4 expression in papillary thyroid cancer (Spearman's r = 0.518, P , 0.0001). Furthermore, TGFBR1 expression was associated with extrathyroidal extension, BRAF mutation, and pathologic TNM stage (Supplemental Fig. 7 ).
DPP4 inhibition suppressed tumor growth in vivo
Finally, we evaluated the role of DPP in thyroid tumor progression in vivo. K1 thyroid cancer cells were injected subcutaneously into each flank of nude mice. We observed a significant reduction of K1 xenograft tumor growth with sitagliptin treatment [P = 0.022; Fig. 5(A) ]. Body weight and blood glucose levels of the mice were not influenced by sitagliptin treatment (Supplemental Fig. 8) . At the time of euthanasia, xenograft tumors were harvested and immunostained with TGFBR1. The TGFBR1 expression was clearly visible at the invasive front of the xenograft tumor. Consistent with our in vitro findings, we observed a decrease in TGFBR1 expression among xenograft tumors of the sitagliptin group [ Fig. 5(B) ]. Collectively, these results highlight the potential for targeting DPP4 in the management of thyroid cancer.
Discussion
Previous studies have shown that DPP4 expression may be an indicator of poor prognosis in certain solid and hematological malignancies. Overexpression of DPP4 or the presence of DPP4-positive cancer stem cells in the primary tumor was associated with distant metastases in esophageal adenocarcinoma and colorectal cancer (17, 18) . In patients with gastrointestinal stromal tumor and colorectal cancer, those exhibiting high DPP4 expression had significantly poorer overall survival (19, 20) . Moreover, the DPP4 positivity predicted an unfavorable clinical outcome among patients with B-cell chronic lymphocytic leukemia (21) . In the current study, we demonstrated that high DPP4 expression is a negative prognostic factor in papillary thyroid cancer in terms of tumor stage and the likelihood of no evidence of disease at follow-up. The mechanisms governing the DPP4 upregulation in malignancies remain largely elusive. It has been shown that TGF-b and c-Myc expression induced DPP4 downregulation, whereas depletion of serum factors was associated with a robust DPP4 upregulation (22, 23) . In renal carcinoma cells, treatment with interferon or cyclic adenosine monophosphate-increasing agents may increase mRNA expression of DPP4 (24) . In this study, we found a higher frequency of BRAF V600E mutation in papillary thyroid cancer with high DPP4 expression. Furthermore, BRAF or MEK inhibitors led to a dosedependent reduction of DPP4 expression [Supplemental Fig. 1(C) ]. In this regard, Arwert and colleagues noted that DPP4 was upregulated in keratinocytes expressing oncogenically activated MEK1, and DPP4 inhibition with sitagliptin reduced wound-induced tumor growth (25) . More rigorous studies are needed to determine the interactions between DPP4 and mitogen-activated protein kinase pathway.
In our study, DPP4 knockdown suppressed various carcinoma phenotypes of thyroid cancer cells, and pharmacological inhibition recapitulated the findings from genetic silencing of DPP4. It suggests that the biological role of DPP4 in thyroid cancer is at least partially mediated by its enzymatic activity. There are conflicting reports on the effects of DPP4 inhibition on tumor progression. Treatment with sitagliptin may decrease colon carcinogenesis and murine mammary tumor growth (26, 27) . Furthermore, the incidence and growth of colorectal lung metastases were reduced with treatment with vildagliptin (28) . By contrast, forced expression of the wild as well as the enzymatically inactive mutant DPP4 suppressed glioma growth in an orthotopic xenotransplantation model (29) . Wang and colleagues recently showed that sitagliptin or saxagliptin treatment promoted metastatic capacity in colon and hepatic xenograft models (30) . These seemingly contradictory findings highlight the importance of cell specificity and heterogeneous oncogenic profiles among different cancer types.
An intriguing finding in our study is that the TGF-b signaling pathway is involved in the regulatory effects of DPP4. Our mouse xenograft model also confirmed that decreased TGFBR1 abundance was associated with significantly reduced tumor volume after sitagliptin treatment. It is generally recognized that TGF-b is a tumor suppressor in the early stage of carcinogenesis, whereas TGF-b can act as a tumor promoter in the late stage of cancer progression (16) . In thyroid tumors, the inhibitory action of TGF-b on cell proliferation is progressively lost as the tumor becomes transformed and more undifferentiated (31, 32) . TGFBR1 inhibition remarkably induced mesenchymal-epithelial transition in anaplastic thyroid cancer cells (33) . Furthermore, TGF-b signaling may cooperate with the mitogen-activated protein kinase pathway. Thyroid cancer cells expressing oncogenic BRAF are more susceptible to epithelial-mesenchymal transition induced by TGF-b (34). Previous studies have shown that DPP4 inhibitors reduced the TGF-b expression and inhibited the development of myocardial or hepatic fibrosis (35, 36) . The rescue effects of TGF-b1 seen in this study suggest that TGF-b signaling plays a crucial role in the functional significance of DPP4 expression in thyroid cancer. Additional studies will have to elucidate the molecular relation between DPP4 inhibition and TGFBR1 downregulation.
The therapeutic potential of targeted therapy using anti-DPP4 monoclonal antibody has been demonstrated in several tumor models (37) . Given the low risk of hypoglycemia and a weight-neutral profile, the use of DPP4 inhibitors among patients with type 2 diabetes has increased steadily since their market debut. The possible association between DPP4 inhibitors and the risk of pancreatic cancer shown in animal experiments has received much attention, but subsequent studies revealed no risk for developing pancreatic cancer (30, 38) . A recent study indicated that DPP4 inhibition may improve adjuvant-based immunotherapy (39) . It is also noteworthy that DPP4 inhibition was associated with a better efficacy of differentiating agents in follicular thyroid cancer cells in terms of increasing iodide uptake (40) . It is therefore possible that incorporating the use of DPP4 inhibitors in patients with diabetes and thyroid cancer may provide an oncologic benefit in a properly selected group of patients.
We acknowledge several limitations of this study. The present clinicopathological investigation of patients with papillary thyroid cancer shared many pitfalls inherent in retrospective studies. The study cohort was selected from a single tertiary academic medical center. In addition, the number of patients studied was small, with a short follow-up period. Our multivariate analysis failed to substantiate that DPP4 expression was an independent predictor of patient outcomes, probably because statistical power was limited or the association was confounded by other factors. Despite these limitations, we found that thyroid cancer with extrathyroidal extension was closely associated with DPP4 overexpression (P , 0.001). It is tempting to speculate that DPP4 may have a direct effect on the tumor invasion process. Given that minimal, microscopic extrathyroidal extension is no longer considered a manifestation of advanced disease according to the eighth edition of the American Joint Committee on Cancer staging system, our findings suggest that those with high DPP4 expression at diagnosis may benefit from heightened surveillance.
Conclusions
We have shown that DPP4 expression is upregulated in malignant thyroid tumors and is associated with tumor aggression and negative prognosis. Pharmacological and genetic inhibition of DPP4 suppresses the aggressive behavior of thyroid cancer cells, including colony formation, cell migration and invasion, and tumor growth in vivo. Finally, we identified that the TGF-b signaling pathway is involved in the regulatory effects of DPP4. Our findings provide evidence that DPP4 could be explored as a therapeutic target in thyroid cancer.
